Tulsa Wealth Advisors INC Invests $709,000 in Edwards Lifesciences Corporation $EW

Tulsa Wealth Advisors INC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, Holdings Channel reports. The fund bought 7,843 shares of the medical research company’s stock, valued at approximately $709,000.

Other large investors have also added to or reduced their stakes in the company. Nippon Life Global Investors Americas Inc. purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $4,674,000. Flputnam Investment Management Co. purchased a new position in Edwards Lifesciences in the 2nd quarter valued at about $455,000. Global Retirement Partners LLC purchased a new position in Edwards Lifesciences in the 2nd quarter valued at about $655,000. 1ST Source Bank purchased a new position in Edwards Lifesciences in the 2nd quarter valued at about $922,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at about $1,274,082,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $91.51 on Monday. The firm has a fifty day moving average of $88.73 and a two-hundred day moving average of $84.38. The firm has a market cap of $52.69 billion, a P/E ratio of 52.59, a P/E/G ratio of 2.30 and a beta of 0.85. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the business posted $0.67 EPS. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EW. BTIG Research lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Citigroup raised their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 25,570 shares of company stock valued at $2,219,390 over the last three months. 0.31% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.